Overview of Flebodia 600

What is Flebodia 600? Overview

Flebodia 600 is an orally administered medication that functions as a specialized phlebotonic and vasoprotective agent used to support the function and structural integrity of the venous and microcirculatory systems. This product falls within the group of Bioflavonoids and is employed in the management of conditions related to impaired venolymphatic insufficiency.

Quick Facts

Property	Description
Active ingredient	Diosmin
Form	Film-coated tablet
Pharmacological class	Vasoprotective and Phlebotonic Agent
General purpose	Supports venous return and capillary stability
Origin	Semisynthetic (derived from citrus bioflavonoids)

Defining Flebodia 600: Pharmacological Class and Purpose

Flebodia 600 is formally classified under the World Health Organization's Anatomical Therapeutic Chemical (ATC) code C05CA03, identifying it as a Bioflavonoid used for capillary stabilization. Its core pharmacological classification is that of a phlebotonic and angioprotective medicine, which means it is intended to provide foundational support to the vascular system. The therapeutic utility of this classification is intended for addressing discomfort associated with compromised venous circulation. The general therapeutic purpose of a phlebotonic agent is to address structural weakness in vein walls and enhance venous return, which is central to stabilizing the circulatory health of the lower limbs, a typical use being in cases of leg heaviness or swelling.

Diosmin Composition, Form, and Differentiation

The single active ingredient in Flebodia 600 is Diosmin, specifically provided as a standardized 600 mg dose of pure Diosmin (anhydrous diosmin). This key ingredient is a semisynthetic compound, originally derived from natural citrus bioflavonoids, or flavonoid precursors. The medicine is a monopreparation, formulated for oral administration as a film-coated tablet designed for efficient peroral delivery. The focus on utilizing the pure, 600 mg form of diosmin distinguishes Flebodia 600 from combination products, representing a key feature in its pharmacological approach to enhancing capillary stabilizing action and improving lymphatic drainage efficiency.

What side effects are possible with Flebodia 600?

Possible Side Effects and Safety Information

The safety profile for Flebodia 600 (Diosmin) is primarily defined by a spectrum of generally mild and transient adverse reactions, mainly affecting the gastrointestinal system.

Adverse Reactions by Frequency

Adverse reactions are classified according to frequency as documented in regulatory sources:

Common (1/100 to < 1/10): Gastralgia (stomach pain).
Uncommon (1/1,000 to < 1/100): Bloating, diarrhea, dyspepsia, and nausea.
Rare (1/10,000 to < 1/1,000): Vomiting, headache, dizziness, and allergic reactions such as skin rash.

Most documented gastrointestinal disorders are minor and rarely require discontinuation of treatment.

Contraindications and Special Warnings

Contraindication: This medication is contraindicated in individuals with known hypersensitivity or allergy to the active substance (Diosmin) or to any of the excipients.
Excipient Warning: The product contains the azo colouring agent, Cochineal Red A (E 124), which may induce allergic reactions.
Acute Haemorrhoids: Administration for acute haemorrhoids should be of short duration and does not replace specific treatment for other underlying anal conditions.

Population-Specific Safety Considerations

Pregnancy: The product should not be used during pregnancy unless deemed clearly necessary by a healthcare professional. Although animal studies have not indicated malformative or fetotoxic effects, sufficient clinical data in pregnant women are limited.
Lactation: Treatment with this medication is generally not recommended while breast-feeding due to the absence of data regarding the passage of the active substance or its metabolites into human milk.
Pediatric Population: The safety and efficacy of the drug in children and adolescents under 18 years of age have not yet been established.

Based on the overall safety profile, the medication is considered to have no or negligible influence on the ability to drive or operate machinery.

Overdose and Emergency Response

Overdose and when to seek help

The official regulatory data on overdose with Flebodia 600 (Diosmin) indicates that clinical experience is limited. When an overdose is suspected or has occurred, the regulatory instruction is explicit: immediate medical attention must be sought.

Documented Manifestations

Regulatory documents describing overdose situations primarily detail adverse events associated with the drug’s general safety profile rather than severe systemic toxicity. The documented manifestations are chiefly confined to the gastrointestinal and integumentary systems. No severe or life-threatening outcomes are formally documented in the official overdose sections of regulatory labeling.

Specific symptoms reported in cases of taking more than the prescribed dose include:

Gastrointestinal events: Nausea, abdominal pain, and diarrhea.
Dermatological events: Skin rash and pruritus (itching).

Required Emergency Action and Management

If an overdose is suspected, patients must consult a doctor or pharmacist immediately. This action is mandated because the management of diosmin overdose should consist of strictly symptomatic and supportive treatment. This means that care will be directed toward addressing the clinical symptoms presented. The official regulatory guidance confirms that no specific antidote is known or available for this medication, and no specific mandatory hospital monitoring requirements are detailed beyond the required immediate medical consultation.

Therapeutic Uses of Flebodia 600

Quick Facts: Uses of Flebodia 600

Supports the management of symptoms associated with chronic venous insufficiency (CVI) of the lower limbs, such as feelings of heaviness, pain, and nocturnal restlessness.
Assists in the relief of functional signs linked to an acute hemorrhoidal episode.
Indicated for additional support in instances of capillary fragility.

What Flebodia 600 Treats: Main Uses and Benefits

Flebodia 600 (containing the active substance diosmin) is a medication that offers therapeutic assistance for specific circulatory conditions. The primary role of this product is to provide symptom relief in people experiencing discomfort associated with venous and lymphatic insufficiency in the legs. This includes common issues such as feelings of leg heaviness, localized pain, and a sensation of restlessness, particularly when attempting to rest. Flebodia 600 is employed to aid in the management of these signs, which relate to chronic venous disease.

Additionally, this medicine is utilized as a supportive measure for the signs and discomfort associated with an acute hemorrhoidal episode. It may also be administered to provide supplemental management for capillary fragility, aiming to offer therapeutic support.

This medication is part of a treatment plan and is most beneficial when combined with appropriate lifestyle measures, such as avoiding prolonged standing and maintaining a balanced weight.

Eligibility and Restrictions for Use

Who Can and Cannot Use Flebodia 600?

Eligibility for Flebodia 600 (Diosmin 600 mg) is strictly defined by regulatory documentation concerning age, hypersensitivity, and physiological status.

The medicine is contraindicated in any individual with a known hypersensitivity to the active substance, diosmin, or to any of the tablet's excipients.

Age and Developmental Restrictions

Flebodia 600 is intended for use in adult populations only. Use is not recommended for children or adolescents under 18 years of age because the safety and efficacy of the product have not yet been established in this age group, according to regulatory bodies.

Physiological Status Limitations

Status	Regulatory Classification
Pregnancy	Should not be used unless clearly necessary (precautionary measure due to limited human data).
Lactation	Treatment is not recommended due to the absence of data regarding passage into breast milk.

Use Limitations

For patients using the medicine for acute hemorrhoids, regulatory documents specify that this administration does not substitute for the specific treatment of other anal diseases, and the course of treatment must be of short duration.

What should I know about interactions with other medicines?

The regulatory interaction profile for Flebodia 600 (Diosmin 600 mg) is established based on official government documentation and post-marketing surveillance data. The primary finding across the authorized product information is the absence of reported clinically relevant interactions with other substances or products.

Official Interaction Status

Category	Regulatory Status
Drug–Drug Interactions	No clinically relevant drug interaction has been reported to date with diosmin.
Metabolic Interactions	No specific pharmacokinetic interactions, such as those involving CYP enzymes or drug transporters, are formally documented in the regulatory interaction section.
Interaction-Related Restrictions	No medicinal products are explicitly listed as contraindicated or requiring mandatory time separation due to an interaction risk.
Food, Alcohol, Herbal Products	Interaction with food, drink, or herbal products is officially noted as "Not applicable" in the regulatory patient information leaflet in terms of interaction risk.

Connection to the Overall Interaction Profile

This documented status means regulatory guidance does not define specific interaction-based constraints regarding co-administration with other medicines. The official interaction map is characterized by a lack of formally required avoidance rules or restrictions related to altered drug clearance or exposure. This profile is derived from safety and surveillance data included in the Summary of Product Characteristics and associated regulatory labeling. There are no population-specific interaction considerations documented in the official labeling.

Mechanism of Action

How Flebodia 600 Works

Flebodia 600 (Diosmin) operates through a distinctive triple-action mechanism focused on the venous and microcirculatory systems, regulating three distinct physiological processes.

Influence on Venous Smooth Muscle Contraction

The molecule potentiates the effect of norepinephrine on alpha-adrenergic receptors in the venous wall. This molecular action leads to increased venous tone and reduced distensibility, which results in reduced venous distensibility and capacity. This functional consequence results in enhanced systemic fluid kinetics.

Modulation of Endothelial Barrier Function

Diosmin influences capillary function by inhibiting the adhesion and activation of leukocytes at the capillary endothelium. This mechanism reduces the local release of inflammatory mediators, which subsequently influences capillary resistance and influences the resistance to fluid filtration into the surrounding tissues.

Modulation of Lymphatic Contractility

The mechanism includes a lymphokinetic effect, where the substance stimulates the contractility of the lymphatic capillaries. This action modulates the frequency and force of lymphatic pumping, influencing the kinetics of interstitial fluid transport.

Dosage and Administration Information

How to Use Flebodia 600

The administration of Flebodia 600 (Diosmin 600 mg) varies depending on the condition being addressed. The drug is provided as a film-coated tablet and is intended for the oral route of administration. The tablet must be swallowed whole with water, without being crushed or altered, to ensure correct delivery of the active substance.

Administration Schedule and Dosing

The following schedules and dose ranges are categorized by use context.

Use Context	Standard Adult Dosing (Daily)	Timing/Frequency	Duration Pattern
Venous Insufficiency	1 tablet (Total 600 mg)	Once daily, in the morning before breakfast	Often long-term, subject to physician re-evaluation
Acute Hemorrhoidal Crisis	2 to 3 tablets (Total 1200 mg to 1800 mg)	Divided daily use, taken during meals	Short-term only, subject to physician re-evaluation

Special Administration Rules

Administration for acute hemorrhoidal episodes is a supportive measure and is not intended to replace specific treatments for other anal diseases. Furthermore, safety and efficacy have not been established for use in the pediatric population (under 18 years of age). Use during pregnancy and lactation is generally not recommended in the absence of sufficient data.

Recent Clinical Evidence

Research evidence / Overview of studies for Flebodia 600

Evidence for Use in Chronic Venous Insufficiency (CVI)

Research on diosmin for Chronic Venous Insufficiency examined Randomized Controlled Trials (RCTs) and systematic reviews that explored how symptoms change over time in adult populations experiencing venous disease. Researchers monitored patient-reported outcomes describing perceived discomfort related to leg heaviness, pain, and nighttime cramps. They also examined objective outcomes related to physical discomfort like leg edema, often measured by leg circumference.

Studies monitored patient-reported outcomes over short-to-intermediate periods, which typically extended up to six months. Research describes observed patterns related to reported symptoms and measurements of swelling. However, long-term effects are not fully established, as follow-up durations were limited in many of the key studies. Furthermore, evidence quality varies across studies, and existing data provides context but not individual predictions due to potential differences between the pure 600 mg diosmin formulation and other similar compounds often grouped together in systematic reviews.

Evidence for Use in Acute Hemorrhoidal Episodes

Diosmin was studied for its application during conditions involving periods of heightened symptoms, specifically acute flare-ups of hemorrhoidal disease. The evidence was evaluated in the context of studies focusing on episodes where symptoms become more noticeable, with observations typically concentrated on very short, acute timeframes, often around one week.

Systematic reviews of the broader phlebotonic class indicate patterns related to symptom intensity or variability when compared to control groups in research settings. Evidence is limited for dedicated, large-scale, recent research focusing strictly on the pure Diosmin 600 mg dose in this specific acute scenario. Because much of the current analysis relies on pooling data from various related flavonoid preparations, subgroup findings are uncertain when attempting to isolate observations for the 600 mg formulation alone.

Evidence in Special Populations and Research Gaps

The existing evidence base primarily reflects the general adult population, and data for certain groups remain insufficient. This limitation is noted especially for patient populations defined by advanced stages of Chronic Venous Disease (e.g., specific CEAP classifications). Sample sizes were modest in some studies, and comparative evidence is lacking for certain groups, such as children or women experiencing pregnancy-related conditions. The research highlights what is known — and what is still uncertain — about the use of diosmin 600 mg in these specialized contexts.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Flebodia 600 (FAQ)

Q: What is the difference between Flebodia 600 and Diosmin-based products?

A: According to the official product information, Flebodia 600 contains the active ingredient as pure Diosmin 600 mg (anhydrous diosmin). This distinguishes it from other diosmin-based products, which are sometimes formulated as a combination with a second bioflavonoid, such as hesperidin.

Q: Is Flebodia 600 the same as other venotonics?

A: Flebodia 600 is classified by health authorities as a type of medicine known as a phlebotonic and vasoprotective agent. This means it is intended to support the health of veins and blood vessels. It belongs to a broad class of medicines but is characterized by its specific active ingredient, Diosmin.

Q: Do you have to take Flebodia 600 forever?

A: The expected duration of use is dependent on the condition being addressed. For chronic conditions like venous insufficiency, use is often long-term but requires periodic re-evaluation by a healthcare professional. Conversely, for acute hemorrhoidal episodes, the treatment is only intended for a short duration.

Q: Does Flebodia 600 affect sleep or cause drowsiness?

A: Official safety information indicates that the medication generally has no or negligible influence on a person's ability to drive or operate machinery. However, documented side effects listed as rare include dizziness and headache.

Q: What is the full list of conditions Flebodia 600 is approved to treat?

A: Official regulatory documents indicate that this medicine is used for the management of symptoms related to Chronic Venous Insufficiency (CVI). It is also approved for supportive care during an Acute Hemorrhoidal Crisis.

Q: Can Flebodia 600 help with leg cramps at night?

A: Clinical studies for chronic venous insufficiency have monitored patient-reported outcomes for symptoms such as pain, swelling, and nighttime cramps. This research describes observed patterns related to the perceived discomfort associated with CVI symptoms.

Q: Are there different strengths of Flebodia besides 600mg?

A: According to the official product labeling and packaging, the Flebodia product is supplied as the 600 mg film-coated tablet. This is the specific dosage strength referenced in the authorized product information.

Q: Is Flebodia 600 used for treating varicose veins or just the symptoms?

A: The medicine is classified as a phlebotonic agent intended to support vascular function. Its purpose is to alleviate the symptoms associated with compromised venous circulation and venous disease, such as leg heaviness, swelling, and discomfort.

Q: What should I look out for if I experience an allergic reaction to Flebodia 600?

A: Official safety information describes signs of allergy, which can include symptoms like skin rash, hives (dermatitis), or swelling. A warning is noted because the tablet contains the coloring agent Cochineal Red A (E 124), which has the potential to induce allergic reactions.

Q: What specific warnings are included in the official labeling for Flebodia 600?

A: Key warnings are noted in the official labeling. Use for acute hemorrhoids is limited to a short duration and does not replace specific underlying treatments for other anal diseases. Additionally, the tablet contains the coloring agent Cochineal Red A (E 124), which may induce allergic reactions.

Q: Does Flebodia 600 require any special monitoring by a doctor?

A: The standard use for chronic venous insufficiency is subject to periodic physician re-evaluation. Official documentation states that for patients with a history of severe liver or kidney disease, the medication is intended to be used with caution and may involve regular monitoring by a healthcare professional.

Q: Is it normal for the side effects of Flebodia 600 to go away after a few weeks?

A: Most documented side effects are classified as mild and transient (short-lasting), particularly gastrointestinal disturbances. These reactions are typically minor and rarely require a person to stop treatment.

Q: Is Flebodia 600 an anti-inflammatory drug?

A: While its primary regulatory classification is as a phlebotonic and vasoprotective agent, the active substance, Diosmin, is described in official chemical libraries and research as having inherent anti-inflammatory properties.

Q: How quickly does Flebodia 600 typically start to show its effects?

A: The time required to observe effects varies depending on the medical condition. For chronic venous insufficiency, clinical studies indicate that symptom improvements, such as reduced leg heaviness or swelling, have been noted over several weeks. For acute hemorrhoidal attacks, symptom relief has been observed in some clinical settings within a few days.

Q: Can Flebodia 600 be used by people with diabetes?

A: Regulatory guidance does not list diabetes as a specific contraindication or special restriction on use. However, clinical research has examined diosmin's potential influence on glucose metabolism.

Q: Is Flebodia 600 safe for elderly patients?

A: The drug is intended for use in the adult population. Official documents indicate that there are no specific age restrictions or dose adjustments defined for use in the elderly population.

Q: Can people with high blood pressure use Flebodia 600?

A: Official regulatory guidance does not list high blood pressure (hypertension) as a specific contraindication or restriction on use in the safety information.

Q: Is a prescription needed for Flebodia 600 in most places?

A: The regulatory status of diosmin products, whether they are available by prescription or as over-the-counter (OTC) medicines, varies significantly based on the country, the local formulation, and the specific dosage authorized by the local health authority.

Q: What if I forget to take a dose of Flebodia 600?

A: Official product instructions state that if a dose is missed, the recommended procedure is to skip the missed dose rather than taking a double dose to compensate, and then continue with the regular dosing schedule.

Q: Why is it important to check drug interactions for Flebodia 600?

A: Although no clinically relevant interactions are reported for many substances, all medicines carry a regulatory requirement to assess interaction potential. This is because certain combinations of drugs could potentially influence efficacy or increase the risk of side effects, such as those affecting the gastrointestinal system.

Q: How is Flebodia 600 absorbed by the body?

A: The product is an orally administered film-coated tablet. After swallowing, the active substance is absorbed and subsequently metabolized in the body to its active form before being eliminated.

Q: Can Flebodia 600 affect liver function tests?

A: Official documentation states that for patients with a history of severe liver or kidney disease, the medication is intended to be used with caution. This is due to the potential influence on how the drug is metabolized and excreted, which may involve regular monitoring by a healthcare professional.

How should Flebodia 600 be stored and disposed of?

Storage and Protection

Flebodia 600 mg film-coated tablets must be stored at a temperature not exceeding 30 C. This is the mandatory requirement for maintaining the stability of the active ingredient, Diosmin, throughout its shelf life. The medicine should be stored in the original packaging (blister pack) to protect the tablets and must be kept strictly out of the sight and reach of children.

Disposal Instructions

Specific instructions for the disposal of unused or expired Flebodia 600 require that the product be discarded in accordance with local regulations for pharmaceutical waste. The medicine should not be disposed of via wastewater or general household waste to minimize environmental impact. Patients should consult a pharmacist or local waste authority for take-back or collection procedures.

Flebodia 600